Work

Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps5099

Authors: Eugene Shenderov, Angelo Demarzo, Karim Boudadi, Mohamad Allaf, Hao Wang, Carolyn Chapman, Christian Pavlovich, Trinity Bivalacqua, Tanya Skelton O'Neal, Rana Harb, Rehab Abdallah, Charles G. Drake, Drew M. Pardoll, Emmanuel S. Antonarakis

Institutions: Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Herbert Irving Comprehensive Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891336772

Cites:

Cited by: 16

Related to: 10